We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Innovative Fusion Device Could Revolutionize Back Surgery

By HospiMedica International staff writers
Posted on 29 Dec 2015
A new spinal fusion device designed to reduce chronic back pain could negate the need for invasive surgery and bone grafts.

Under development by researchers at the University of New South Wales (UNSW; Sydney, Australia) the Thru–Fuze device is made of porous titanium that promotes bone growth and fusion both on and through the device after it is placed between the vertebrae. More...
Over time, the device acts as a bridge between adjacent vertebrae for additional bone growth, resulting in rapid biomechanical fixation, without the need for a bone graft procedure or supporting metallic hardware.

According to the researchers, the device will allow faster, simpler surgery with minimal radiation exposure compared to current methods. Preclinical and laboratory testing in animal models has demonstrated rapid biomechanical fixation between the fusion device and the vertebrae. Human trials of the Thru-Fuze are expected to begin at the Prince of Wales Hospital (Sydney, NSW, Australia) in late 2016, with future commercialization of the device exclusively licensed to Intellectual Ventures (Bellvue, WA, USA). Patents for the technology have been filed in Australia, Europe, China, and the United States.

“Existing methods of spinal fusion use rod or cage systems that require screws to be drilled into the spine and a painful bone graft harvested, which is the material used to form the bridge and obtain the fusion between the vertebrae in the spine,” said device inventor Prof. Bill Walsh, MD, director of surgical and orthopedic laboratories at UNSW. “These systems are very costly, difficult and time consuming to implant and they also have variable rates of fusion success. Existing methods rely on the bone to make its way right across the vertebrae and it can take up to a year to find out if the surgery has been a success.”

“New technologies such as the Thru-Fuze are of paramount importance, as surgeons strive to deliver better patient outcomes with less invasive and more effective implant and prostheses options,” said neurosurgeon Ralph Mobbs, MD, who will lead the human trials. “The potential of the device is significant.”

Related Links:

University of New South Wales 
Intellectual Ventures



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Hospital Data Analytics App
Alarm History Analytics
New
Measuring Rod
seca 233
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.